Pharma Two B Ltd.
3 Pekeris Street
Weizmann Science Park
Rehovot
76702
Tel: 00972-8- 9472672
Fax: 00972- 8- 9366832
Website: http://www.pharma2b.com/
21 articles with Pharma Two B Ltd.
-
Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders®
9/15/2022
Pharma Two B Ltd. today announced that positive efficacy and safety data from its recently completed randomized, controlled Phase 3 trial of investigational P2B001.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting
4/5/2022
Pharma Two B Ltd today announced that the efficacy and safety data from its recently completed Phase 3, randomized controlled trial of P2B001 in the management of early Parkinson’s disease is being presented today, April 5th.
-
Discover what's in store for today's presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
-
Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson’s Disease (PD)
1/20/2022
Pharma Two B Ltd. today announced that it will host a key opinion leader (KOL) event to discuss the positive results from the pivotal Phase III Study of P2B001 in early Parkinson’s Disease (PD) on Thursday, January 27, 2022 from 11am – 12pm Eastern Time.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease
12/15/2021
Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components.
-
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease
12/15/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson’s disease (PD) successfully met its primary and key secondary endpoints.
-
Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea
11/18/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation of previously approved drugs for neurological indications, today announced that it has entered into an exclusive licensing agreement with Myung In Pharm Co. Ltd (“Myung In Pharm”) to commercialize P2B001 for Parkinson’s disease (PD) in South Korea.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease
9/13/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced that the last patient in its multinational Phase III study of P2B001 in early PD has now completed the study.
-
BioSpace Movers & Shakers, Aug. 27
8/27/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors
8/23/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.
-
Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors
8/12/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.
-
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive OfficerDr. Oren Has 25 Years’ Experience in Global Drug Development Leadership; Proven Track Record in PD
1/5/2021
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced that Sheila Oren, M.D., M.B.A., was appointed Chief Executive Officer of Pharma Two B, effective January 1, 2021.
-
Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer
2/18/2020
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced today the appointment of David S. Tierney M.D. as Chief Executive Officer, effective immediately as well as the establishment of a fully owned U.S. subsidiary to serve as the marketing base of the Company’s activities.
-
Pharma Two B Ltd. Release: First Patients Dosed in Phase III Multi-Center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson's Disease
2/6/2018
"This fundraising enables Pharma Two B to complete the Phase III and expand its pipeline."
-
Pharma Two B Ltd. Closes $30 Million Financing Round
2/27/2017
-
Pharma Two B Ltd. Announces Positive Results In Its Phase Ilb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease
6/30/2015
-
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25
7/2/2014